Maze Therapeutics, INC Form 4 insider transactions

Maze Therapeutics director Jonathan E. Lim was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Sekar Kathiresan, a Director at Maze Therapeutics, Inc., was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics Director Charles J. Homcy was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics Director Neil Exter acquired 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Nancy C Andrews, a Director at Maze Therapeutics, Inc., was granted 18,000 stock options with an exercise price of $23.67, vesting monthly over nine months starting October 1, 2025.

Maze Therapeutics Director Richard H. Scheller sold all 20,744 shares of common stock for approximately $22.37 per share in a pre-planned transaction.

Maze Therapeutics' Chief Financial Officer, Tahir Misbah, was granted 325,000 stock options with an exercise price of $15.32.

Maze Therapeutics Director Neil Exter was granted 16,000 stock options with an exercise price of $13.35, vesting monthly over 16 months.

Third Rock Ventures files Form 4 detailing the conversion of preferred stock to common stock and changes in beneficial ownership following Maze Therapeutics' initial public offering.

Director Jonathan E. Lim reports changes in beneficial ownership of Maze Therapeutics stock following the conversion of preferred stock and option transactions.

Director Charles J. Homcy reports changes in beneficial ownership of Maze Therapeutics stock and derivative securities following the company's IPO and related conversions.